Contralateral prophylactic mastectomy and survival: An ongoing challenge

Annals of Surgical Oncology

Volumn 21, Issue 11, 2014, Pages 3372-3374

  Bedrosian, Isabelle ^a   Yao, Kathy ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; COMORBIDITY; CONTRALATERAL PROPHYLACTIC MASTECTOMY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EDITORIAL; FAMILY HISTORY; GENE MUTATION; HUMAN; MASTECTOMY; OVERALL SURVIVAL; PATIENT SATISFACTION; RISK REDUCTION; BREAST NEOPLASMS; FEMALE; MORTALITY;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY;

EID: 84922586806     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3938-5     Document Type: Editorial

References (11)

1. Yao K, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. 2013;142:465–76.
2. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23:4275–86.
3. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:401–9.
4. Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564–9.
5. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009;101:1058–65.
6. Early Breast Cancer Trialists’ Collaborative Group. Polychemo-therapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–42.
7. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56:1038–45.
8. Reiner AS, John EM, Brooks JD, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31:433–9.
9. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118:5637–43.
10. Abbott A, Rueth N, Pappas-Varco S, Kuntz K, Kerr E, Tuttle T. Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol. 2011;18:3129–36.
11. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159:373–81.